Veru Inc.: Veru Reports Fiscal 2023 First Quarter Financial Results
Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by multiple global regulatory agencies Presented late-breaker oral presentation at IDWeek; sabizabulin treatment
Source: finanznachrichten.de